NEW YORK (GenomeWeb News) – Shares of Foundation Medicine soared in their debut on the Nasdaq Global Select Market this morning.

The Cambridge, Mass.-based cancer genomics analysis firm said after the close of the market yesterday that it had launched its initial public offering of about 5.9 million shares at $18 per share.

In early Wednesday trade, the stock was up around 80 percent at $32.31.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.